- Home
- ZGM vs SCLX Comparison
ZGM vs SCLX Comparison
Compare ZGM & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGM
- SCLX
- Stock Information
- Founded
- ZGM 2019
- SCLX 2011
- Country
- ZGM Macau
- SCLX United States
- Employees
- ZGM N/A
- SCLX N/A
- Industry
- ZGM Professional Services
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- ZGM Consumer Discretionary
- SCLX Health Care
- Exchange
- ZGM Nasdaq
- SCLX Nasdaq
- Market Cap
- ZGM 43.6M
- SCLX 35.7M
- IPO Year
- ZGM 2025
- SCLX N/A
- Fundamental
- Price
- ZGM $4.00
- SCLX $18.73
- Analyst Decision
- ZGM
- SCLX Strong Buy
- Analyst Count
- ZGM 0
- SCLX 3
- Target Price
- ZGM N/A
- SCLX $367.50
- AVG Volume (30 Days)
- ZGM 277.2K
- SCLX 309.9K
- Earning Date
- ZGM 01-01-0001
- SCLX 08-13-2025
- Dividend Yield
- ZGM N/A
- SCLX N/A
- EPS Growth
- ZGM 401.52
- SCLX N/A
- EPS
- ZGM 0.17
- SCLX N/A
- Revenue
- ZGM $3,620,780.00
- SCLX $44,236,000.00
- Revenue This Year
- ZGM N/A
- SCLX $89.26
- Revenue Next Year
- ZGM N/A
- SCLX $203.95
- P/E Ratio
- ZGM $23.39
- SCLX N/A
- Revenue Growth
- ZGM 211.78
- SCLX N/A
- 52 Week Low
- ZGM $2.00
- SCLX $3.60
- 52 Week High
- ZGM $4.51
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- ZGM N/A
- SCLX 46.04
- Support Level
- ZGM N/A
- SCLX $14.80
- Resistance Level
- ZGM N/A
- SCLX $30.90
- Average True Range (ATR)
- ZGM 0.00
- SCLX 3.47
- MACD
- ZGM 0.00
- SCLX -1.47
- Stochastic Oscillator
- ZGM 0.00
- SCLX 23.68
About ZGM Zenta Group Company Limited Ordinary Shares
Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.